<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03486379</url>
  </required_header>
  <id_info>
    <org_study_id>IRCCS-CROB</org_study_id>
    <nct_id>NCT03486379</nct_id>
  </id_info>
  <brief_title>Folfiri as Third Line of Treatment</brief_title>
  <official_title>FOLFIRI as a Second-line Therapy in Patients With Docetaxel-pretreated Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Cancer Referral Center of Basilicata</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Cancer Referral Center of Basilicata</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the activity of Folfiri as Third line of treatment in
      mGC progressed after ramuciramb-based second line.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">March 23, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>response rate (confirmed complete and partial response).</measure>
    <time_frame>From date of enrollment to best radiological evaluation, up to 12 months</time_frame>
    <description>rate of patients with complete or partial response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
    <description>Time from start of treatment to Progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of enrollment until the date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
    <description>Time from start of treatment to Death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>From date to start therapy up to 12 months</time_frame>
    <description>Incidence of Toxicity according National Cancer Institute Common Terminology Criteria</description>
  </secondary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Ramucirumab</condition>
  <condition>Third Line</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic gastric cancer progressed after two lines of treatment including
        ramucirumab-based therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed, ramucirumab pretreated metastatic gastric
             cancer who received

          -  Eastern Cooperative Oncology Group performance status ≤2 (ECOG PS)

          -  aged &gt; 18 years

          -  neutrophil count ≥1500/μl

          -  platelet count ≥100 000/μl),

          -  renal (serum creatinine ≤1.5 mg/dl)

          -  liver (serum bilirubin ≤2 mg/dL) functions

          -  normal cardiac function,

          -  absence of second primary tumor other than non-melanoma skin cancer

          -  no concurrent uncontrolled medical illness.

        Exclusion Criteria:

          -  Eastern Cooperative Oncology Group performance status &gt;2 (ECOG PS)

          -  No prior treatment with ramucirumab

          -  operable metastatic disease were excluded from the study

          -  severe cardiac dysfunction, congestive heart failure or a recent myocardial infarction

          -  uncontrolled sites of infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Cancer Referral Center of Basilicata</investigator_affiliation>
    <investigator_full_name>Giandomenico Roviello</investigator_full_name>
    <investigator_title>MS, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

